New cell therapy trial offers hope for patients with untreatable blood cancer
NCT ID NCT07234721
Summary
This is an early safety study testing a new cell therapy called SL4903 for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target the cancer, and infuse them back. The main goal is to find a safe dose and see if the treatment shows any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.